title: Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
abstract: BACKGROUND
  Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) incidence in the United States increases with age. Given the progressive ageing of the general population, incidence of these diseases is likely to continue to rise in the future. There is an acute need for therapeutic developments because of the poor prognosis of these diseases. Since the knowledge of molecular genetics in AML and MDS has expanded recently, targeted therapeutics should offer an exciting new frontier for advancement. Of all the targeted inhibitors developed, tipifarnib represents one of the few compounds with some activity as a single agent.
  
  
  METHODS
  Described in this review are the molecular targets of tipifarnib, safety and tolerability of the drug, chemistry, and clinical efficacy in AML.
  
  
  RESULTS
  The reader will gain a thorough understanding of tipifarnib as it relates to the current and future use of the drug in AML.
  
  
  CONCLUSIONS
  The future of tipifarnib, along with other molecularly-targeted drugs, lies in achieving a better understanding of leukemia biology and harnessing the activity of this agent using predictive biomarkers for improved patient selection.
authors.affiliation: Moffitt Cancer Center, Tampa, FL 33647, USA.
authors.forename: Pearlie K
authors.initials: PK
authors.lastname: Epling-Burnette
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Loughran
mesh_terms: D000367:Age Factors; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D011379:Prognosis; D015363:Quinolones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015363:Quinolones; D051231:Farnesyltranstransferase; C402769:tipifarnib
references.citation: Leukemia. 2009 Apr;23(4):631-4
references.pmid: 19092853
references.citation: Trends Biochem Sci. 1993 Sep;18(9):349-53
references.pmid: 8236454
references.citation: Oncogene. 1997 Feb 6;14(5):623-5
references.pmid: 9053862
references.citation: Immunol Rev. 2007 Aug;218:114-25
references.pmid: 17624948
references.citation: Tumori. 1989 Aug 31;75(4):337-40
references.pmid: 2683276
references.citation: Mini Rev Med Chem. 2009 Jun;9(6):638-52
references.pmid: 19519490
references.citation: Cancer Genet Cytogenet. 2008 Jun;183(2):89-93
references.pmid: 18503825
references.citation: Blood. 2007 Jun 15;109(12):5151-6
references.pmid: 17351110
references.citation: Blood. 2003 Nov 1;102(9):3349-53
references.pmid: 12842991
references.citation: Clin Cancer Res. 2003 Oct 15;9(13):4761-71
references.pmid: 14581347
references.citation: Rev Recent Clin Trials. 2007 May;2(2):135-41
references.pmid: 18473998
references.citation: Curr Opin Investig Drugs. 2002 Feb;3(2):313-9
references.pmid: 12020065
references.citation: Hematology Am Soc Hematol Educ Program. 2002;:136-61
references.pmid: 12446422
references.citation: Blood. 2004 May 1;103(9):3271-7
references.pmid: 14726402
references.citation: J Clin Oncol. 2002 Jun 1;20(11):2726-35
references.pmid: 12039935
references.citation: Blood. 2009 Aug 6;114(6):1166-73
references.pmid: 19470696
references.citation: Cancer Control. 2003 Sep-Oct;10(5):384-7
references.pmid: 14581893
references.citation: Leukemia. 2002 Sep;16(9):1664-7
references.pmid: 12200678
references.citation: Leukemia. 2006 Apr;20(4):635-44
references.pmid: 16467864
references.citation: Br J Haematol. 2000 Dec;111(3):873-4
references.pmid: 11122149
references.citation: Eur J Haematol. 2006 Jul;77(1):51-6
references.pmid: 16573741
references.citation: Oncogene. 1997 Sep;15(11):1283-8
references.pmid: 9315095
references.citation: Leukemia. 2003 Feb;17(2):451-7
references.pmid: 12592346
references.citation: Blood. 2006 May 15;107(10):3847-53
references.pmid: 16434492
references.citation: Cancer Res. 2001 Jan 1;61(1):131-7
references.pmid: 11196150
references.citation: Blood. 2001 Jun 1;97(11):3361-9
references.pmid: 11369625
references.citation: J Biol Chem. 1995 Nov 10;270(45):26802-6
references.pmid: 7592920
references.citation: Cancer. 2003 May 1;97(9):2229-35
references.pmid: 12712476
references.citation: Leukemia. 2003 May;17(5):849-55
references.pmid: 12750696
references.citation: Leuk Lymphoma. 2001 Sep-Oct;42(5):847-53
references.pmid: 11697639
references.citation: Cell Cycle. 2005 Nov;4(11):1540-9
references.pmid: 16205124
references.citation: Leukemia. 1994 Apr;8(4):638-41
references.pmid: 7512175
references.citation: Blood. 2009 May 14;113(20):4841-52
references.pmid: 19109557
references.citation: Leuk Lymphoma. 2006 Jul;47(7):1387-91
references.pmid: 16923573
references.citation: Blood. 2000 Sep 1;96(5):1655-69
references.pmid: 10961860
references.citation: J Lipid Res. 2006 Jan;47(1):15-31
references.pmid: 16278491
references.citation: Leukemia. 1988 Aug;2(8):503-10
references.pmid: 3166076
references.citation: Biochem Soc Trans. 1996 Aug;24(3):692-9
references.pmid: 8878828
references.citation: Blood. 2008 Jul 1;112(1):45-52
references.pmid: 18443215
references.citation: Blood. 2008 Mar 1;111(5):2589-96
references.pmid: 18160667
references.citation: Clin Cancer Res. 2009 May 1;15(9):3076-83
references.pmid: 19383813
references.citation: Cancer. 2007 Apr 15;109(8):1536-42
references.pmid: 17345612
references.citation: Hum Mol Genet. 2004 May 15;13(10):1081-93
references.pmid: 15044383
references.citation: Blood. 2003 Mar 1;101(5):1692-7
references.pmid: 12411300
references.citation: Int J Cancer. 2007 Nov 15;121(10):2317-30
references.pmid: 17657738
references.citation: Blood Rev. 2003 Sep;17(3):123-9
references.pmid: 12818222
references.citation: Blood. 1993 Jul 15;82(2):590-9
references.pmid: 8329714
references.citation: Clin Cancer Res. 2008 May 15;14(10):3077-82
references.pmid: 18483374
references.citation: Cancer Res. 2009 May 1;69(9):3910-7
references.pmid: 19383925
references.citation: Nature. 1993 May 6;363(6424):85-8
references.pmid: 8479541